Last reviewed · How we verify
Lodosyn
At a glance
| Generic name | Lodosyn |
|---|---|
| Sponsor | University of Miami |
| Target | Lysine-specific demethylase 4E, Aromatic-L-amino-acid decarboxylase, Tyrosine-protein kinase Fyn |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Approved indications
- Parkinson's disease
- Parkinsonism
- Postencephalitic parkinsonism
Common side effects
Key clinical trials
- Single-Center, Open, Randomized, Single-Dose, Completely Repeated Crossover Bioequivalence Study to Evaluate the Effects of the Test/Reference Preparation, Entacapone,Levodopa and Carbidopa Tablets (I (Phase 1)
- Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE) (Phase 1)
- Screening Medications for Cocaine Cessation and Relapse Prevention (Phase 2)
- Continuous Delivery of Levodopa/Carbidopa (Duodopa) in Patients With Advanced Idiopathic Parkinsons Disease - a Health Economic Evaluation (Phase 4)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-104: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre Firs (Phase 1)
- A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patient (Phase 2)
- Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects (Phase 3)
- Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa: a Doubleblind, Randomized, F (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lodosyn CI brief — competitive landscape report
- Lodosyn updates RSS · CI watch RSS
- University of Miami portfolio CI